全文获取类型
收费全文 | 39714篇 |
免费 | 3240篇 |
国内免费 | 1149篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 860篇 |
妇产科学 | 515篇 |
基础医学 | 6226篇 |
口腔科学 | 794篇 |
临床医学 | 2721篇 |
内科学 | 6087篇 |
皮肤病学 | 702篇 |
神经病学 | 3456篇 |
特种医学 | 615篇 |
外国民族医学 | 5篇 |
外科学 | 3125篇 |
综合类 | 5274篇 |
现状与发展 | 4篇 |
预防医学 | 1841篇 |
眼科学 | 486篇 |
药学 | 6275篇 |
3篇 | |
中国医学 | 1962篇 |
肿瘤学 | 2961篇 |
出版年
2023年 | 703篇 |
2022年 | 1034篇 |
2021年 | 1549篇 |
2020年 | 1372篇 |
2019年 | 1541篇 |
2018年 | 1519篇 |
2017年 | 1413篇 |
2016年 | 1283篇 |
2015年 | 1353篇 |
2014年 | 2216篇 |
2013年 | 2445篇 |
2012年 | 2031篇 |
2011年 | 2467篇 |
2010年 | 1951篇 |
2009年 | 1989篇 |
2008年 | 1991篇 |
2007年 | 1770篇 |
2006年 | 1643篇 |
2005年 | 1534篇 |
2004年 | 1442篇 |
2003年 | 1253篇 |
2002年 | 1082篇 |
2001年 | 816篇 |
2000年 | 790篇 |
1999年 | 669篇 |
1998年 | 506篇 |
1997年 | 510篇 |
1996年 | 453篇 |
1995年 | 465篇 |
1994年 | 400篇 |
1993年 | 291篇 |
1992年 | 239篇 |
1991年 | 246篇 |
1990年 | 185篇 |
1989年 | 155篇 |
1988年 | 167篇 |
1987年 | 132篇 |
1986年 | 143篇 |
1985年 | 289篇 |
1984年 | 304篇 |
1983年 | 239篇 |
1982年 | 269篇 |
1981年 | 215篇 |
1980年 | 198篇 |
1979年 | 181篇 |
1978年 | 135篇 |
1977年 | 95篇 |
1976年 | 103篇 |
1975年 | 91篇 |
1973年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
目的 借助网络药理学的方法,探究两组王琦教授新冠肺炎预防方(简称预防方)预防新型冠状病毒肺炎(COVID-19)的分子靶点和机制。方法 通过TCMSP数据库检索并筛选其活性成分及其作用靶点,通过Uniprot数据库进行蛋白标准化处理。从Genecards数据库中以“Novel coronavirus pneumonia”为关键词搜索获取COVID-19的靶标,构建相交靶点韦恩图。通过cytoscape3.7.2构建PPI蛋白互作网络,寻找富集数目最多的靶点。通过R语言对预防方治疗COVID-19的靶点进行GO和KEGG富集分析,并绘制气泡图。结果 预防方与新冠肺炎相关靶点涉IL-6、TNF、CXCL8、VEGFA、MMP9;GO功能富集分析分别获得53、57条通路;27、29条KEGG相关信号通路。结论 王琦教授新冠肺炎预防方中的主要活性成分为槲皮素、山奈酚、木犀草素、β-谷甾醇、植物甾醇等,可能通过作用于IL-6、TNF、CXCL8、VEGFA、MMP9、CXCL8、IL10、CCL2、IL1B等靶点和介导TNF信号通路、T细胞受体信号通路、Toll样受体信号通路等发挥作用,从而促进免疫反应、炎症反应及细菌防御反应,预防COVID-19。 相似文献
12.
13.
14.
15.
《Vaccine》2021,39(40):5729-5731
IntroductionConcerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination.MethodsImmune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1–7 shedding was tested with a multiplexed PCR.ResultsIn 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1).DiscussionWe did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2. 相似文献
16.
17.
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding Cassette Subfamily C Member 4 (ABCC4) polymorphisms on hematotoxicity in pediatric patients who received a standard low starting dose of 6-MP. One hundred and sixty-nine pediatric patients were enrolled and their genotypes were determined. Patients who carried NUDT1513 and NUDT1512 genotypes were at a 10–15 fold higher risk of severe neutropenia than those of the wild-type during the early months of the maintenance phase. Risk of neutropenia was not significantly increased in patients with other NUDT15 variants as well as in patients with TPMT, ITPA or ABCC4 variants. These results suggest that NUDT15 polymorphisms particularly, NUDT1513 and NUDT1512, play major roles in 6-MP-induced severe hematotoxicity even when using a standard low dosage of 6-MP and genotyping of these variants is necessary in order to obtain precise tolerance doses and avoid severe hematotoxicity in pediatric patients. 相似文献
18.
19.
IntroductionRadiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports.Materials and methodsAll patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated.ResultsData of 53 patients were analyzed. The median age at diagnosis was 72 (range 44–89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36–172) months. The median radiation dose was 57.6 (range 34–66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3–66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period.ConclusionThe present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear. 相似文献
20.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献